MedImmune is increasingly concentrating its workforce in Maryland, both through new hires and consolidations from California, as it prepares to take a host of midstage drug candidates through clinical trials.
The Gaithersburg biotech is entering a pivotal period. Its parent, British pharmaceutical giant AstraZeneca PLC, is laying off employees by the thousands at the same time that it is investing more heavily in its Maryland-based biologics arm.